Progressive Corporation has just reported August earnings, and the options market is flashing its most defensive reading of the past year — even as short sellers remain firmly on the sidelines.
The standout signal this week is in options, not short interest. The put/call ratio has jumped to 1.10, nearly three standard deviations above its 20-day average of 0.98 — and that 2.89 z-score is the most elevated reading in at least 12 months, hitting a fresh 52-week high. That is a meaningful step up from the modestly cautious 0.99 ratio noted ahead of the print just days ago. The shift tells you options traders have moved from mild hedging to something closer to active downside positioning in the wake of the release.
Short interest tells a far quieter story. Bears have continued to pull back — SI has dropped roughly 9% over the past week to 1.4% of the free float, with borrow costs drifting lower to 0.40% and availability remaining effectively unlimited at over 580 million shares in the lending pool. There is no meaningful short-side pressure here, and the ORTEX short score of 30 confirms it. The divergence between options defensiveness and short market calm is the week's central tension: options traders are reaching for protection, but few are prepared to put on an outright short.
The analyst community has been cutting targets with some consistency since the July earnings cycle. Cantor Fitzgerald lowered its target this week to $200 from $220, maintaining a Neutral rating. JP Morgan moved to $241 from $250 post-earnings, also holding Neutral. Morgan Stanley upgraded from Underweight to Equal-Weight in late July with a $210 target — still well below the consensus mean of $229. B of A Securities, the most constructive voice, carries a Buy and a $308 target, but that now sits nearly 50% above the current price of $207, making it a clear outlier. Wells Fargo remains at Underweight with a $198 target, one of the few below the current price. The broad direction of travel is targets coming down; the dispute is whether the stock is fairly valued after its roughly 10% year-to-date decline or still stretched. The EPS momentum factor score of just 20 over 30 days supports the bear case that estimates are still moving the wrong way. The forward earnings yield at 8% and a P/E of 12.5x are more modest than PGR's historical premium, though the forward earnings growth score of just 3 out of 100 underscores the market's scepticism on the growth outlook.
Insider activity adds a further nuance. CEO Susan Griffith sold nearly 37,400 shares at $212.71 on July 27 — a $7.9 million transaction — with the CFO, CIO, and several divisional presidents executing smaller sales around the same date and price. The 90-day net insider position, once awards are included, is nominally positive at 175,000 shares, but that figure is flattered by the CEO's large stock award on July 24. The actual cash selling by senior management in the $211–$220 range over the past three weeks suggests leadership was comfortable locking in at prices above where the stock now trades.
Among close peers, PGR's weekly decline of 2.4% stands out against most of the group. Erie Indemnity added 3.7% on the day and is flat on the week, while Allstate and Chubb each lost less than 0.5% over the same period. W.R. Berkley and ACGL both edged higher on the week. The relative underperformance is notable and consistent with the pattern from recent weeks, where PGR has lagged the broader insurance group on what appear to be company-specific valuation and growth concerns rather than sector-wide pressure.
The next scheduled earnings event is November 3. Between now and then, the questions worth tracking are whether the post-print options defensiveness fades as the PCR reverts toward its 20-day average, and whether the analyst community stabilises targets or continues to walk them lower as loss-ratio and premium growth data rolls in monthly.
See the live data behind this article on ORTEX.
Open PGR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
